Ruxolitinib,Paclitaxel,Carboplatin
NRG Oncology,novartis,incyte
['ovarian', 'ruxolitinib']
the nrg-gy007 study will be presented by from during #asco22 this morning. gy007 studied ruxolitinib with frontline neoadjuvant &amp; post-surgical therapy in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. 
Advancing cancer research, improving lives.